Sagimet Biosciences to Participate in the 8th Annual Evercore ISI Healthcare Conference

Core Insights - Sagimet Biosciences Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways [1][3] Company Overview - Sagimet is developing FASN inhibitors aimed at conditions caused by the overproduction of the fatty acid palmitate [3] - Denifanstat, an oral medication, has successfully met all primary endpoints in its Phase 2b FASCINATE-2 clinical trial for MASH and in a Phase 3 clinical trial for moderate-to-severe acne in partnership with a licensee in China [3] - A combination therapy of denifanstat and resmetirom is currently undergoing a Phase 1 PK clinical trial, with plans for development in cirrhotic patients with F4-stage MASH [3] - TVB-3567, another oral FASN inhibitor, is in a Phase 1 first-in-human clinical trial for acne [3] Upcoming Events - Management will participate in the 8th Annual Evercore ISI Healthcare Conference on December 2, 2025, with a fireside chat scheduled for 12:55 PM ET [1] - A webcast of the event will be available on Sagimet's website, with an archived replay accessible for 90 days post-event [2]